文献速递呼吸道感染呼吸危重症与机械通气

COVID-19相关ARDS中ACE2表达上调与肺泡II型细胞丢失

Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19-related Acute Respiratory Distress Syndrome.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

该研究回顾性分析两个队列的肺组织免疫荧光染色和血清ACE浓度,发现COVID-19相关与无关ARDS患者肺组织ACE2表达均上调而ACE降低,但肺泡II型细胞(AT2)减少仅见于COVID-19相关ARDS。

要点

  • COVID-19相关与无关ARDS肺组织ACE2表达均上调,ACE降低。
  • AT2细胞减少仅见于COVID-19相关ARDS,提示损伤后修复受损。
  • 血清ACE2升高、ACE降低在两类ARDS中均可见。

核心结论

  • COVID-19相关与无关ARDS患者肺组织和血清中ACE2均上调、ACE降低,但AT2细胞减少仅见于COVID-19相关ARDS。

研究设计与样本

  • 回顾性分析两个不同患者队列的肺组织多重免疫荧光染色和血清ACE浓度。
  • 肺组织染色标记AT2细胞(ProSPC)和内皮细胞(CD31)。

主要发现

  • 肺组织ACE2表达在COVID-19相关和无关ARDS中分别为组织面积的0.06%和0.12%,对照组为0.006%(P=0.013和P<0.0001)。
  • ACE2在内皮细胞中表达上调(0.32%和0.53% vs. 0.01%;P=0.009和P<0.0001),但在AT2细胞中未上调(0.13%和0.08% vs. 0.03%;P=0.94和P=0.44)。
  • 肺组织ACE表达在COVID-19相关和无关ARDS中均降低(P=0.057和P=0.032)。
  • 血清ACE2升高和ACE降低在COVID-19(P=0.0054和P<0.0001)和非COVID-19 ARDS(P<0.0001和P=0.016)中均可见。
  • COVID-19相关ARDS患者AT2细胞较COVID-19无关ARDS患者减少(1.395% vs. 2.94%,P=0.0033)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: ACE2 (angiotensin-converting enzyme 2), the entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is expressed in type 2 alveolar epithelial cells (AT2) that may play key roles in postinjury repair. An imbalance between ACE2 and ACE has also been hypothesized to contribute to lung injury. Objectives: To characterize the expression and distribution of ACE2 and ACE and to compare AT2 with endothelial cell expression in coronavirus disease (COVID-19)-related or -unrelated acute respiratory distress syndrome (ARDS) and controls. Methods: Lung tissue stainings (using multiplex immunofluorescence) and serum concentrations of ACEs were determined retrospectively in two different cohorts of patients. AT2 and endothelial cells were stained in lung tissue for ProSPC (pro-surfactant protein C) and CD31, respectively. Measurements and Main Results: Pulmonary ACE2 expression was increased in patients with COVID-19-related and -unrelated ARDS (0.06% of tissue area and 0.12% vs. 0.006% for control subjects; P = 0.013 and P < 0.0001, respectively). ACE2 was upregulated in endothelial cells (0.32% and 0.53% vs. 0.01%; P = 0.009 and P < 0.0001) but not in AT2 cells (0.13% and 0.08% vs. 0.03%; P = 0.94 and P = 0.44). Pulmonary expression of ACE was decreased in both COVID-19-related and -unrelated ARDS (P = 0.057 and P = 0.032). Similar increases in ACE2 and decreases in ACE were observed in sera of COVID-19 (P = 0.0054 and P < 0.0001) and non-COVID-19 ARDS (P < 0.0001 and P = 0.016). In addition, AT2 cells were decreased in patients with COVID-19-related ARDS compared with COVID-19-unrelated ARDS (1.395% vs. 2.94%, P = 0.0033). Conclusions: ACE2 is upregulated in lung tissue and serum of both COVID-19-related and -unrelated ARDS, whereas a loss of AT2 cells is selectively observed in COVID-19-related ARDS.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Gerard L, Lecocq M, Bouzin C, et al. Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19-related Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2021. PMID: 34449302. doi:10.1164/rccm.202012-4461OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。